Test Price
2,800 AED✅ Home Collection Available
TCF12 Gene Craniosynostosis Type 3 Genetic Test in UAE | 2800 AED | DNA Labs UAE
Executive Summary & Core Metrics
Executive Summary
- 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Next Generation Sequencing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation from our Consultant Medical Genetics.
- Direct Billing Verification: WhatsApp +971 54 548 8731.
This advanced genetic test, performed in our ISO 9001:2015 accredited laboratory, achieves 99.9% diagnostic sensitivity for TCF12 mutations causing craniosynostosis type 3, delivering reliable results and specialist medical guidance to families across the UAE.
Test Overview & Methodology
The TCF12 NGS test identifies pathogenic variants in the TCF12 gene, the most common cause of syndromic coronal craniosynostosis, providing high diagnostic specificity for type 3 craniosynostosis. Whole gene sequencing via next generation technology detects single nucleotide variants, small insertions and deletions with superior accuracy compared to traditional Sanger sequencing.
| Feature | Our TCF12 NGS Test | Closest Alternative (Single-Gene Sanger Sequencing) |
|---|---|---|
| Precision | 99.9% sensitivity, full gene coverage | ~95% sensitivity, limited to known hot-spots |
| Method | Next Generation Sequencing (NGS) | Sanger Sequencing |
| Turnaround Time | 3 to 4 Weeks | 6 to 8 Weeks |
Physician Insight & Safety Protocols
“As a DHA-licensed Consultant Medical Genetics, I strongly recommend integrating TCF12 genetic testing with a thorough clinical and radiological assessment. A negative result does not eliminate other genetic causes of craniosynostosis. Families should seek multidisciplinary counselling before making any medical decisions based on test outcomes.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Clinical Advisory
Do not discontinue any prescribed medication or alter treatment regimens without explicit consultation with your treating physician. This genetic test is an adjunct to, not a replacement for, comprehensive clinical evaluation by a qualified specialist.
Exclusion Criteria & Emergency Red Flags
- Unable to provide sufficient blood volume (minimum 1 mL whole blood).
- Known severe coagulopathy or active bleeding disorder untreated.
- Signs of acute increased intracranial pressure: persistent vomiting, lethargy, bulging fontanelle, sunset eyes.
- Respiratory distress requiring immediate medical stabilization.
If any of the above red flags are present, seek emergency care before scheduling the genetic test.
Patient FAQ & Clinical Guidance
1. What is the TCF12 Gene Craniosynostosis Type 3 Genetic Test?
This advanced genetic test sequences the entire TCF12 gene using next generation technology to identify pathogenic mutations responsible for craniosynostosis type 3. The analysis detects single nucleotide variants and small indels with high sensitivity, enabling accurate diagnosis, prognosis, and recurrence risk counselling for affected families.
2. How should I prepare for the blood sample collection?
No fasting or medication adjustments are required. Simply provide a complete clinical history and attend the home collection appointment in a relaxed state. A certified phlebotomist will draw a small volume of peripheral whole blood using sterile, temperature-controlled cold-chain procedures.
3. What does a positive result mean for my child?
A positive TCF12 mutation confirms a genetic diagnosis of craniosynostosis type 3. This result guides surgical planning, timing of intervention, and provides accurate recurrence risk information for future pregnancies. Your specialist will discuss the implications in depth and coordinate multidisciplinary care with paediatric neurosurgery and genetics teams.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection
This test is performed under DHA Facility License Number 1143. DNA Labs UAE adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields for all genomic data handling, storage, and transmission.
Clinical safety and patient consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability. All genetic counselling and result disclosure are conducted by DHA-licensed professionals in compliance with UAE healthcare regulations.
Clinical & Logistical Metadata
| Test Name | TCF12 Gene Craniosynostosis Type 3 Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (minimum 1 mL) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM |
| Methodology Used | Next Generation Sequencing (NGS) – Full Gene Coverage |
| ICD-10-CM Code | Q75.0 |
| LOINC Code | 94222-8 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians